These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 29340619)
1. Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register. Subesinghe S; Rutherford AI; Byng-Maddick R; Leanne Hyrich K; Benjamin Galloway J Rheumatology (Oxford); 2018 Apr; 57(4):651-655. PubMed ID: 29340619 [TBL] [Abstract][Full Text] [Related]
2. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917 [TBL] [Abstract][Full Text] [Related]
3. Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Subesinghe S; Rutherford AI; Byng-Maddick R; Hyrich KL; Galloway JB Rheumatology (Oxford); 2018 Dec; 57(12):2096-2100. PubMed ID: 29986108 [TBL] [Abstract][Full Text] [Related]
4. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rutherford AI; Patarata E; Subesinghe S; Hyrich KL; Galloway JB Rheumatology (Oxford); 2018 Jun; 57(6):997-1001. PubMed ID: 29529307 [TBL] [Abstract][Full Text] [Related]
5. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Bechman K; Clarke BD; Rutherford AI; Yates M; Nikiphorou E; Molokhia M; Norton S; Cope AP; Hyrich KL; Galloway JB Rheumatology (Oxford); 2019 Oct; 58(10):1767-1776. PubMed ID: 30982886 [TBL] [Abstract][Full Text] [Related]
6. The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Matcham F; Davies R; Hotopf M; Hyrich KL; Norton S; Steer S; Galloway J Rheumatology (Oxford); 2018 May; 57(5):835-843. PubMed ID: 29447376 [TBL] [Abstract][Full Text] [Related]
7. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862 [TBL] [Abstract][Full Text] [Related]
8. Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Bechman K; Halai K; Yates M; Norton S; Cope AP; ; Hyrich KL; Galloway JB Arthritis Rheumatol; 2021 Oct; 73(10):1800-1809. PubMed ID: 33844458 [TBL] [Abstract][Full Text] [Related]
9. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ; Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785 [TBL] [Abstract][Full Text] [Related]
10. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Fu B; Ustianowski AP; Watson KD; Lunt M; Symmons DP; ; Rheumatology (Oxford); 2011 Jan; 50(1):124-31. PubMed ID: 20675706 [TBL] [Abstract][Full Text] [Related]
11. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL; Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304 [TBL] [Abstract][Full Text] [Related]
12. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP; Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999 [TBL] [Abstract][Full Text] [Related]
13. British Society for Rheumatology Biologics Register. Silman A; Symmons D; Scott DG; Griffiths I Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144 [TBL] [Abstract][Full Text] [Related]
14. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [TBL] [Abstract][Full Text] [Related]
15. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Nakajima A; Saito K; Kojima T; Amano K; Yoshio T; Fukuda W; Inoue E; Taniguchi A; Momohara S; Minota S; Takeuchi T; Ishiguro N; Tanaka Y; Yamanaka H Mod Rheumatol; 2013 Sep; 23(5):945-52. PubMed ID: 23073692 [TBL] [Abstract][Full Text] [Related]
16. The British Society for Rheumatology biologics register. Watson K; Symmons D; Griffiths I; Silman A Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv42-3. PubMed ID: 16239385 [TBL] [Abstract][Full Text] [Related]
17. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Symmons DP; Ann Rheum Dis; 2011 Oct; 70(10):1810-4. PubMed ID: 21784730 [TBL] [Abstract][Full Text] [Related]
18. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800 [TBL] [Abstract][Full Text] [Related]
19. Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Cipriani P; Berardicurti O; Masedu F; D'Onofrio F; Navarini L; Ruscitti P; Maruotti N; Margiotta DP; Liakouli V; Di Benedetto P; Carubbi F; Valenti M; Cantatore FP; Afeltra A; Giacomelli R Clin Rheumatol; 2017 Feb; 36(2):251-260. PubMed ID: 27783237 [TBL] [Abstract][Full Text] [Related]
20. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort. Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]